Annual Report 2016 Active Biotech AB (publ)
May 18 2017 - 8:30AM
Active Biotech's Annual Report 2016 is now
available för download at www.activebiotech.com.
The Annual Report will only be digitally distributed. The English
version will be available within short.
Lund, May 18, 2017
Tomas Leanderson
President & CEO
For further information, please
contact:
Hans Kolam, CFO
Tel. +46 (0)46 192044
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a
biotechnology company with focus on neurodegenerative/inflammatory
diseases and cancer. Laquinimod, an orally administered small
molecule with unique immunomodulatory properties, is in Phase 2
development for the treatment of primary progressive multiple
sclerosis and Huntington's disease. Anyara, cancer immunotherapy,
previously in clinical Phase 1-2/3 development in patients with
pancreatic-, lung- or renal cancer. Furthermore, commercial
activities are conducted for the tasquinimod, paquinimod and SILC
projects. Please visit www.activebiotech.com for more
information.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
This information is information
that Active Biotech AB is obliged to make public pursuant to the
Securities Markets Act. The information was submitted for
publication at 14.30 am CET on May 18, 2017.
Annual Report 2016 Active Biotech
AB (publ)
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
